CA2153688A1 - 2,6-diaminopurine derivatives - Google Patents

2,6-diaminopurine derivatives

Info

Publication number
CA2153688A1
CA2153688A1 CA002153688A CA2153688A CA2153688A1 CA 2153688 A1 CA2153688 A1 CA 2153688A1 CA 002153688 A CA002153688 A CA 002153688A CA 2153688 A CA2153688 A CA 2153688A CA 2153688 A1 CA2153688 A1 CA 2153688A1
Authority
CA
Canada
Prior art keywords
ethyl
amino
purin
deoxy
aminol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002153688A
Other languages
English (en)
French (fr)
Inventor
Michael Gregson
Barry Edward Ayres
George Blanch Ewan
Frank Ellis
John Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2153688A1 publication Critical patent/CA2153688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002153688A 1993-01-20 1994-01-18 2,6-diaminopurine derivatives Abandoned CA2153688A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9301000.7 1993-01-20
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (1)

Publication Number Publication Date
CA2153688A1 true CA2153688A1 (en) 1994-08-04

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002153688A Abandoned CA2153688A1 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives

Country Status (29)

Country Link
US (2) US5925624A (enExample)
EP (1) EP0680488B1 (enExample)
JP (1) JP3768232B2 (enExample)
KR (1) KR960700261A (enExample)
CN (1) CN1043997C (enExample)
AP (1) AP457A (enExample)
AT (1) ATE164849T1 (enExample)
AU (1) AU679714B2 (enExample)
CA (1) CA2153688A1 (enExample)
CZ (1) CZ187995A3 (enExample)
DE (1) DE69409503T2 (enExample)
DK (1) DK0680488T3 (enExample)
EC (1) ECSP941104A (enExample)
ES (1) ES2117249T3 (enExample)
FI (1) FI953489A7 (enExample)
GB (1) GB9301000D0 (enExample)
HU (1) HU211914A9 (enExample)
IL (1) IL108372A (enExample)
IS (1) IS4121A (enExample)
NO (1) NO305603B1 (enExample)
NZ (1) NZ259880A (enExample)
PE (1) PE54194A1 (enExample)
PL (1) PL309975A1 (enExample)
RU (1) RU2129561C1 (enExample)
SI (1) SI9400021A (enExample)
SK (1) SK281229B6 (enExample)
TW (1) TW267168B (enExample)
WO (1) WO1994017090A1 (enExample)
ZA (1) ZA94335B (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000963B1 (ru) * 1995-05-30 2000-08-28 Рон-Пуленк Роре С.А. Производные 2-азабицикло[2.2.1]гептана, способ их получения и их применение
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
UA62996C2 (en) * 1998-02-26 2004-01-15 Aventic Pharmaceuticals Inc 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2334200C (en) 1998-06-02 2011-01-25 Cadus Pharmaceutical Corporation Pyrrolo[2,3d]pyrimidine compositions and their use
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
EE200000768A (et) * 1998-06-23 2002-04-15 Glaxo Group Limited 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
IL150062A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
EA008241B1 (ru) * 2000-04-25 2007-04-27 Айкос Корпорейшн Ингибиторы фосфатидилинозитол-3-киназы дельта человека
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DK1406667T3 (da) * 2001-07-06 2008-06-16 Topigen Pharmaceuticals Inc Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
IL161867A0 (en) * 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE60234376D1 (de) 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
US7022681B2 (en) * 2002-08-15 2006-04-04 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
RU2416412C2 (ru) 2004-10-29 2011-04-20 Топиджен Фармасьютикалз Инк. Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
BRPI0518861B8 (pt) 2004-12-17 2021-05-25 Anadys Pharmaceuticals Inc compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20130020850A (ko) 2005-10-21 2013-02-28 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
JP5117391B2 (ja) 2005-11-21 2013-01-16 アナディス ファーマシューティカルズ インク ５−アミノ−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンを調製するための新規な方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE496924T1 (de) 2006-06-22 2011-02-15 Anadys Pharmaceuticals Inc Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP2192905A4 (en) 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2743642C (en) 2008-11-13 2017-09-19 Calistoga Pharmaceuticals, Inc. Therapies for hematologic malignancies
HRP20121006T1 (hr) 2009-01-29 2013-01-31 Novartis Ag Supstituirani benzimidazoli za lijeäśenje astrocitoma
JP2012521994A (ja) 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
MX2012008049A (es) 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
DK2822954T3 (en) 2012-12-21 2016-05-30 Gilead Sciences Inc POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
NO2865735T3 (enExample) 2013-07-12 2018-07-21
SMT201700498T1 (it) 2013-07-12 2017-11-15 Gilead Sciences Inc Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (enExample) 2014-06-20 2018-06-23
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2018030184A1 (ja) * 2016-08-10 2018-02-15 株式会社スリーボンド エポキシ樹脂組成物およびこれを含む導電性接着剤
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
DE3576344D1 (de) * 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
DE3810551A1 (de) * 1987-04-06 1988-11-03 Sandoz Ag Neue ribofuranuronsaeure-derivate
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
CA2028002A1 (en) * 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0708781B1 (en) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists

Also Published As

Publication number Publication date
ES2117249T3 (es) 1998-08-01
EP0680488A1 (en) 1995-11-08
WO1994017090A1 (en) 1994-08-04
IS4121A (is) 1994-07-21
JPH08505864A (ja) 1996-06-25
PL309975A1 (en) 1995-11-13
DE69409503D1 (de) 1998-05-14
ZA94335B (en) 1994-10-24
HU211914A9 (en) 1996-01-29
IL108372A0 (en) 1994-04-12
PE54194A1 (es) 1995-01-06
SI9400021A (en) 1994-09-30
CN1043997C (zh) 1999-07-07
NZ259880A (en) 1996-11-26
DE69409503T2 (de) 1998-08-06
AU5885194A (en) 1994-08-15
KR960700261A (ko) 1996-01-19
GB9301000D0 (en) 1993-03-10
ATE164849T1 (de) 1998-04-15
CZ187995A3 (en) 1996-01-17
NO952872L (no) 1995-09-13
CN1119440A (zh) 1996-03-27
US5889178A (en) 1999-03-30
SK91895A3 (en) 1996-04-03
NO952872D0 (no) 1995-07-19
SK281229B6 (sk) 2001-01-18
NO305603B1 (no) 1999-06-28
FI953489L (fi) 1995-09-13
AU679714B2 (en) 1997-07-10
DK0680488T3 (da) 1999-01-25
IL108372A (en) 1998-06-15
ECSP941104A (es) 1994-12-15
FI953489A0 (fi) 1995-07-19
US5925624A (en) 1999-07-20
RU2129561C1 (ru) 1999-04-27
EP0680488B1 (en) 1998-04-08
AP457A (en) 1996-02-01
AP9400613A0 (en) 1994-01-31
JP3768232B2 (ja) 2006-04-19
FI953489A7 (fi) 1995-09-13
TW267168B (enExample) 1996-01-01

Similar Documents

Publication Publication Date Title
CA2153688A1 (en) 2,6-diaminopurine derivatives
US5424295A (en) 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine
US5668113A (en) Method of using 1,5-anhydrohexitol nucleoside analogues to treat viral infections
DE60026861T2 (de) Purin-derivate
US6350735B1 (en) Purine derivatives
DE602005005240T2 (de) 4'-C-substituierte 2-Haloadenosinderivate
TWI232217B (en) Antiviral pharmaceutical composition comprising 1,3-oxathiolane nucleoside analogues and a further therapeutic agent
DE60005502T2 (de) 4'-c-ethynyl-purin-nukleoside
DD297650A5 (de) Verfahren zur herstellung von fluor-substituierten purin-nucleosiden und sie enthaltender pharmazeutischer zubereitungen
DD296687A5 (de) Nucleosid-derivate und deren verwendung als arzneimittel
US5430027A (en) 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias
US4863906A (en) 2'-deoxy-5-ethynyluridine-3',5'-diestens for treatment of VZV and CMV infections
US5663154A (en) 2',3'-dideoxy-3'-fluoro-purine ribonucleosides
PT90788B (pt) Processo de preparacao de esteres de nucleosidos 5-alcinil-pirimidinicos e de composicoes farmaceuticas que os contem
JPS6284086A (ja) グアニン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued